No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AQST240517P2500
- 0.10
- +0.05+100.00%
15min DelayClose May 8 12:01 ET
0.10High0.08Low
0.08Open0.05Pre Close11 Volume1.19K Open Interest2.50Strike Price90.00Turnover178.97%IV-22.20%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.10Time Value100Contract SizeAmericanOptions Type-0.1850Delta0.3096Gamma30.85Leverage Ratio-0.0130Theta-0.0002Rho-5.71Eff Leverage0.0013Vega
Intraday
- 5D
- 1D
News
Aquestive Therapeutics Inc (AQST) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Palatin Technologies (PTN)
Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Aquestive Therapeutics (AQST) and Inspire Medical Systems (INSP)
Express News | Aquestive Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results
Aquestive Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Aquestive Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Aquestive Therapeutics Presents to Investors and Analysts
Comments
$Aquestive Therapeutics(AQST.US$
NEWS
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Positive
Successful completion of Phase 3 study for Anaphylm in Q1 2024
Received FDA approval for Libervant for patients ages two to five
Extended cash runway into 2026 through underwritten public offering
Progressed clinical studies for AQST-108 in dermatology conditions
Increase in total revenues from $11.1 million in Q1 2023 to $12.1 million in Q1 2024
Negati...
NEWS
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Positive
Successful completion of Phase 3 study for Anaphylm in Q1 2024
Received FDA approval for Libervant for patients ages two to five
Extended cash runway into 2026 through underwritten public offering
Progressed clinical studies for AQST-108 in dermatology conditions
Increase in total revenues from $11.1 million in Q1 2023 to $12.1 million in Q1 2024
Negati...
2
3
See summary 👇
📣 4 PDUFAs upcoming in May:
$Dynavax Technologies(DVAX.US$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4 Pharmaceuticals(XFOR.US$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
📣 4 PDUFAs upcoming in May:
$Dynavax Technologies(DVAX.US$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4 Pharmaceuticals(XFOR.US$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
6
2
$Aquestive Therapeutics(AQST.US$ they trying to beat down price prior to earning reporting. then will shoot up. NFA
1
Read more
JESSE JAMES8832 : let it get beat down so i can buy it up
Jaguar8OP JESSE JAMES8832: Your wish will be granted
JESSE JAMES8832 Jaguar8OP: at least i get my way somehow llol